153 results on '"Caminal-Montero, L."'
Search Results
2. AB1240 NLRP3 AND CASP1 GENES AS DISCRIMINATORY MARKERS BETWEEN IGA VASCULITIS AND IGA NEPHROPATHY?
3. AB0806 HUMORAL RESPONSES AGAINST HDL ARE LINKED TO UNFAVORABLE LIPOPROTEIN TRAITS AND LIPID SPECIES IN PRIMARY SJÖGREN SYNDROME
4. POS0256 THE FIRST METHYLOME PROFILING STUDY OF B-CELLS IN IGA VASCULITIS REVEALED POTENTIAL BIOMARKERS OF DISEASE SUSCEPTIBILITY
5. Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients
6. AB0173 MUCOSAL IMMUNE DEFENCE POLYMORPHISMS: RELEVANT PLAYERS IN IGA VASCULITIS?
7. AB0166 IGAV AND IGAN: A SINGLE ENTITY REGARDING CD40, BLK AND BANK1 POLYMORPHISMS
8. Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients
9. TRATAMIENTO ANTIBIÓTICO SUPRESIVO EN PACIENTES CON ENDOCARDITIS INFECCIOSA
10. ANCA-associated hypertrophic pachymeningitis, a central nervous system limited type of systemic vasculitis
11. AB0145 IgA VASCULITIS AND IgA NEPHROPATHY SHARE A SIMILAR IL33-IL1RL1 ASSOCIATION PATTERN
12. AB0146 BAFF, APRIL y BAFFR: DIFFERENTIAL BIOMARKERS BETWEEN IgA VASCULITIS AND IgA NEPHROPATHY?
13. Influence of the IL17A locus in giant cell arteritis susceptibility
14. POS0113 BAFF-APRIL-BAFFR PATHWAY ON THE PATHOGENESIS OF IMMUNOGLOBULIN-A VASCULITIS
15. AB0096 IGA VASCULITIS AND IGA NEPHROPATHY SHARE A SIMILAR IL17A ASSOCIATION PATTERN
16. Reply to “High frequency of Antiphospholipid Antibodies in Critically ill COVID‐19 patients: a Link with Hypercoagulability?”
17. ANCA-associated hypertrophic pachymeningitis, a central nervous system limited type of systemic vasculitis.
18. Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort
19. PS8:171 Endothelial dysfunction and vascular risk factors in patients with systemic lupus erythematosus
20. PS9:174 Prevalence of vascular risk factors in a cohort study of patients in follow-up in a unit of autoimmune diseases in a 3th level hospital in spain
21. PS3:63 Not all patients with lupus are similar
22. Off-label use of rituximab for systemic lupus erythematosus in Europe
23. Impact of Commercial Strain Use on Saccharomyces cerevisiae Population Structure and Dynamics in Pinot Noir Vineyards and Spontaneous Fermentations of a Canadian Winery
24. Registry of the Spanish Network for Systemic Sclerosis
25. Registry of the Spanish network for systemic sclerosis: Survival, prognostic factors, and causes of death
26. FRI0463 Survival and Mortality Analysis in a Large Cohort of Spanish Patients with Anti-JO1 Antisynthetase Syndrome from the Geas-IIM Group
27. Miocarditis y enfermedad de Still del adulto
28. Anti-ribosomal P antibodies are associated with elevated circulating IFNα and IL-10 levels in systemic lupus erythematosus patients
29. AB0542 Blocking the Human B Lymphocyte Stimulator Molecule (BLYS) Using A Monoclonal Antibody (Belimumab) in Systemic Lupus Erythematosus: First Results in Real-Life Spanish Patients with Refractory Disease (Biogeas-Semi Registry)
30. Tratamiento de la encefalopatía de Wernicke
31. A case of polymyositis associated with the presence of anti-proliferating cell nuclear antigen antibodies, a marker typically considered SLE specific
32. Úlceras orales y esofágicas en paciente infectado por VIH
33. Mouth and Esophageal Ulcers in an HIV-infected Patient
34. Reply to "High frequency of Antiphospholipid Antibodies in Critically ill COVID‐19 patients: a Link with Hypercoagulability?".
35. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases
36. [Tuberculous pancreatitis in HIV infection]
37. Influence of the IL17A locus in giant cell arteritis susceptibility
38. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases
39. Tuberculous pancreatitis in HIV infection,Pancreatitis tuberculosa en la infección por el VIH
40. Circulating levels of Low Density Granulocytes and cell-free DNA as predictors of cardiovascular disease and bone deterioration in SLE patients.
41. Resolution of cardiac involvement with cobimetinib in Erdheim-Chester disease.
42. Entities inside one another: VEXAS, a matryoshka-type disease.
43. Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism.
44. Clostridioides difficile recovered in pleural fluid: Contamination or infection? A case report of a proven empyema and a literature review.
45. Mucosal Immune Defence Gene Polymorphisms as Relevant Players in the Pathogenesis of IgA Vasculitis?
46. ANCA-associated hypertrophic pachymeningitis, a central nervous system limited type of systemic vasculitis.
47. Comments: Recommendations for prevention of infection in systemic autoimmunerheumatic diseases.
48. Non-Cirrhotic Portal Hypertension in Systemic Lupus Erythematosus.
49. Ureaplasma parvum Septic Arthritis, a Clinic Challenge.
50. IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.